Streetbeat News

Products Services

PLTR

AI security firm CalypsoAI has partnered with Palantir Technologies Inc. (NYSE:PLTR) to use Palantir's FedStart program. CalypsoAI's security platform will be made available to government agencies through FedStart, providing an accredited environment for AI security and other application deployments. The partnership will allow for rapid adoption of CalypsoAI's solutions by a greater number of government customers.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:32 pm

TTMI

TTM Technologies, Inc. (NASDAQ:TTMI) has announced plans to establish a new high-tech manufacturing facility in New York State. The facility will produce ultra-HDI PCBs and is expected to be the highest-technology PCB manufacturing facility in North America. The project will create an estimated 400 manufacturing and engineering jobs in Central New York and support an equal number of construction jobs. The groundbreaking is anticipated in the first half of 2024, with the project's final scale, scope, and timeline subject to finalizing funding with various stakeholders.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:32 pm

LEXX

Lexaria Bioscience Corp. (NASDAQ:LEXX) is expanding its studies of its proprietary DehydraTECH platform in the GLP-1 drug space, a market estimated to reach $82.93 billion by 2027. The company's early studies in 2022 showed positive effects of lowering glucose levels, body weight, and triglyceride levels, and increased locomotor activity.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:31 pm

BSGM

BioSig Technologies, Inc. (NASDAQ:BSGM) has been awarded five new utility patents by the U.S. Patent and Trademark Office, expanding its intellectual property portfolio to over 100 patents. The patents cover the company's PURE EP™ digital signal processing technology and AI. The PURE EP™ Platform is currently in a national commercial launch and is part of healthcare systems including Mayo Clinic, Texas Cardiac Arrhythmia Institute, Cleveland Clinic, and Kansas City Heart Rhythm Institute.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:30 pm

IBIO

iBio, Inc. (IBIO) has announced the expansion of its AI-powered technology stack with the launch of ShieldTx, a patent-pending antibody masking technology. This technology is designed to enable specific, highly targeted antibody delivery to diseased tissue without harming healthy tissue. The company used ShieldTx to develop masks for its MUC16-targeted bispecific antibody candidates, which were previously developed using iBio's patented Epitope Steering and EngageTx™ AI Platforms. The new technology could potentially increase the safety and developability of therapeutic antibodies for difficult targets and modes of action.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:29 pm

FRSX

Foresight Autonomous Holdings Ltd. (FRSX) is focusing on defense, industrial vehicles, and Eye-Net Mobile initiatives in the short term. The company has signed several agreements and achieved milestones in these sectors, including a $4 million deal with Elbit Systems and a $51 million deal with SUNWAY-AI Technology. Foresight is also pursuing projects in the automotive industry, with partnerships with Hitachi Astemo and ZF Friedrichschafen. The company's Eye-Net subsidiary has partnered with SoftBank and received an order from a leading Japanese vehicle manufacturer.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:28 pm

CVAC

GSK

CureVac N.V. (NASDAQ:CVAC) has announced progress in its Phase 2 clinical vaccine development programs for COVID-19 and seasonal flu, conducted in collaboration with GSK. The COVID-19 Phase 2 study, which compares mono- and bivalent vaccine candidates against a licensed comparator COVID-19 vaccine, has been fully enrolled. The first participant has been dosed in the seasonal flu Phase 2 part of a combined Phase 1/2 study. Interim Phase 2 data for both programs are expected in 2024.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:27 pm

ZVSA

ZyVersa Therapeutics (NASDAQ:ZVSA) has announced a publication in Molecular Neurobiology that reinforces data showing that its Inflammasome ASC Inhibitor IC 100 can attenuate the inflammatory response causing neuronal damage in a multiple sclerosis model. The study demonstrated that NLRP3 inflammasomes play a significant role in the pathogenesis of multiple sclerosis, and that their inhibition can lead to significant decreases in neuronal damage and demyelination. ZyVersa is developing IC 100 to inhibit the formation of multiple types of inflammasomes and their associated ASC specks to attenuate damaging inflammation.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:26 pm

AMD

NVDA

Semiconductor companies NVIDIA Corp (NVDA) and Advanced Micro Devices Inc (AMD) saw their stock prices rise due to the boom in cryptocurrencies. However, after Ethereum's switch from Proof-of-Work to Proof-of-Stake, the need for GPUs in crypto mining decreased. Despite this, the AI industry's upswing since 2023 has kept the demand for GPUs high. Comparing the performance of NVDA and AMD after Ethereum's switch, NVDA's stock price increased by 215.61% while AMD's rose by 28.49%.

Portfolio Pulse from Mehab Qureshi

November 01, 2023 | 12:20 pm

SLE

Super League Enterprises (NASDAQ:SLE) has been granted a new patent by the United States Patent and Trademark Office (USPTO) for AI-driven optimization of live streaming content. The patent pertains to the production and intelligent prioritization of simultaneous perspectives within virtual environments, particularly video games. The company's creative studio has been a significant contributor to its business, producing content for brands like MTV and Samsung.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:19 pm